Targos Team
Management
Thomas Henkel
Chief Executive Officer & Co-Founder
About
Dr. Thomas Henkel
Chief Executive Officer
Co-Foundert
As a trained scientist Dr. Henkel ventured into US and German biotechnology to develop therapeutics and diagnostics. In 2005 he co-founded Targos to meet the increasing demand for professional biomarker services. His entrepreneurial leadership and innovation management skills helped to grow Targos into a sustainable, commercially successful business.
Publications
Publications:
Stoss, O., Henkel, T. Role of Central Laboratories in Research, Validation, and Application of Predictive Biomarkers. Predictive Biomarkers in Oncology - Applications in Precision Medicine. 2019 Chapter 51, p 559-567 Editors Badve S and Kumar GK, Springer Nature, ISBN 978-3-319-95227-7
Scheel AH, Baenfer G, Baretton G, Dietel M, Diezko R, Henkel T, Heukamp LC,
Jasani B, Jöhrens K, Kirchner T, Lasitschka F, Petersen I, Reu S, Schildhaus HU,
Schirmacher P, Schwamborn K, Sommer U, Stoss O, Tiemann M, Warth A, Weichert W, Wolf J, Büttner R, Rüschoff J. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology. 2018
Feb;72(3):449-459. doi: 10.1111/his.13375.
Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B,
Untch M, Rüschoff J. Impact of updated HER2 testing guidelines in breast
cancer--re-evaluation of HERA trial fluorescence in situ hybridization data. Mod
Pathol. 2015 Dec;28(12):1528-34.
König K, Peifer M, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Stamm K,
Ueckeroth F, Vollbrecht C, Bos M, Gardizi M, Scheffler M, Nogova L, Leenders F,
Albus K, Meder L, Becker K, Florin A, Rommerscheidt-Fuss U, Altmüller J, Kloth M,
Nürnberg P, Henkel T, Bikár SE, Sos ML, Geese WJ, Strauss L, Ko YD, Gerigk U,
Odenthal M, Zander T, Wolf J, Merkelbach-Bruse S, Buettner R, Heukamp LC.
Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis
and Therapy of Lung Cancer Patients. J Thorac Oncol. 2015 Jul;10(7):1049-57.
Rüschoff J, Nagelmeier I, Hofmann M, Henkel T, Stoss O. ErbB2 diagnostics in breast cancer--an update. Pathologe. 2009 Mar;30(2):147-55.
Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008 Jun;52(7):797-805.
Stoss O, Werther M, Zielinski D, Middel P, Jost N, Ruschoff J, Henkel T, Albers P.
Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(2):166-72; Epub 2007 Jul 24.
Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmoller P, Gutjahr T, Kaufmann M,
Henkel T, Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin(R)) Phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy., J Clin Pathol. 2008 Jan;61(1):89-94. Epub 2007 Apr 5.
Stoss O, Jost N, Czeloth K, Ruschoff J, Henkel T, Albers P. Urologe A. 2007 Sep;46(9):1117-9.
Gaiser T, Hofmann M, Stoss O, Henkel T, Rüschoff J.
Her-2/neu analysis--new data? Verh Dtsch Ges Pathol. 2006; 90:107-13.
Roessler M., Rollinger W., Mantovani-Endl L., Hagmann M._L., Palme S., Berndt P., Engel A., Pfeffer M, Karl J, Bodenmueller H, Rüschoff J, Henkel T, Rohr G., Rossol S., Rösch W., Langen H., Zolg W, and Tacke M (2006) Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis
Mol. Cell. Proteomics August 6, 2006, 10.1074/mcp.M600118-MCP200
Roessler, M., Rollinger, W., Palme, S., Hagmann, ML., Berndt, P., Engel, AM.,
Schneidinger, B., Pfeffer, M., Andres, H., Karl, J., Bodenmuller, H., Ruschoff, J., Henkel, T., Rohr, G., Rossol, S., Rosch, W., Langen, H., Zolg, W., Tacke, M. (2005)
Identification of Nicotinamide N-Methyltransferase as a Novel Serum Tumor Marker for Colorectal Cancer. Clin Cancer Res. 2005 Sep 15;11(18):6550-6557.
Stoss, O. and Henkel T. (2004) Biomedical marker molecules for cancer – current status and perspectives. Drug Discovery Today Targets, 3(6), 228-237
Schmidtgen, C. and Henkel T. (2004) Gewebebanken in der Biomedizinischen Forschung. BioForum 1/04
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and Henkel, T. (2003) Emerging molecular targets for chronic heart failure (Part II). Exp. Opinion Therap.Targets 7(1):pp
Roenicke, V, Stoss, O., Szado, T., Leclair, S., Kirsch, T., Hoffmann, A., Navé, B.T. and Henkel, T. (2002) Emerging molecular targets for chronic heart failure (Part I). Exp.Opinion Therap.Targets 6(6):649-658
Stoss, O., Reuner, B. and Henkel, T. (2002) RNA Expression profiling in cardiac tissue – a successful route to new drug targets? Targets 1, 12-19
Nave, B.T., Becker, M., Roenicke, V., Henkel, T. (2002) Validation of targets and drug candidates in an engineered three-dimensional cardiac tissue model.
Drug Discov Today Apr 1;7(7):419-425
Funk, M., Niedenthal, R., Mumberg, D., Brinkmann, K., Rönicke, V. and Henkel, T. (2002)
Vectors systems for the heterologous expression of proteins in Saccharomyces cerevisiae. In Guide to Yeast Genetics and Molecular Cell Biology Part B, Methods in Enzymology, Vol 350: 248
Henkel, T. (1999) Therapeutic Innovation. IDrugs 2(5):403-404
Henkel, T. & Klein, H.-G. (1998) Differentielle Genexpression. Medizinische Genetik 2:356
Hsieh, J.J.D, Henkel, T., Salmon, P., Robey, E., Peterson, M.G. and Hayward, S.D. (1996) Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr Virus EBNA-2. Mol. Cell. Biol. 16, 952-959
Traenckner, E.B.M, Pahl, H.L., Henkel, T., Schmidt, K.N., Wilk, S. and Baeuerle, P.A. (1995) Phosphorylation of human IκB- on serines 32 and 36 controls IκB-α proteolysis and NF-κB activation in response to diverse stimuli. EMBO J. 14, 2876-2883
Henkel, T., Ling, P.D., Hayward, S.D. and Peterson, M.G. (1994) Mediation of Epstein-Barr Virus EBNA2 trans-activation by Recombination Signal-Binding Protein Jκ. Science, 265, 92 - 95.
Baeuerle, P.A. and Henkel, T. (1994) Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12, 141-179.
Groß, N. A., Henkel, T., Karabinos, A., Götz, H., Barnikol-Watanabe, S. and Hilschmann, N. (1994) Human protein NEFA, a novel DNA binding/EF-hand/ leucine zipper protein - Molecular cloning and sequence analysis of the cDNA, isolation and characterization of the protein. Biol. Chem. Hoppe Seyler, 375, 497-512
Machleidt, T., Wiegmann, K., Henkel, T., Schütze, S., Baeuerle, P. and Krönke, M.
(1994), Sphingomyelinase activates proteolytic IκB-a degradation in a cell-free system.
J. Biol. Chem. 269, 13760-13765
Henkel, T., Machleidt, T., Alkalay I., Krönke M., Ben-Neriah, Y. and P.A. Baeuerle
(1993) Rapid proteolysis of IκB- is necessary for activation of transcription factor NF-κB. Nature 365, 182-185
Zabel, U., Henkel, T., dos Santos Silva, M. and Baeuerle, P.A. (1993) Nuclear uptake
control of NF-κB by MAD-3, an IκB protein present in the nucleus. EMBO J. 12, 201-211
Henkel, T., Schmitz, M.L. and Baeuerle, P.A. (1993) Rapid characterization of lambda cDNA clones after amplification and radioactive labeling with the PCR technique. BioTechniques, 14 (6), 3 - 4
Henkel, T and P.A. Baeuerle (1993) Functional analysis of mutated cDNA clones by direct use of PCR products in in vitro transcription/translation reactions. Anal. Biochem. 214, 351-352
Henkel, T., Zabel, U., van Zee, K., Müller, J., Fanning, E. and Baeuerle, P.A. (1992) Intramolecular masking of the nuclear location signal and dimerization domain in the precursor of the p50 NF-κB subunit. Cell 68, 1121-1133
Ruben, S., Dillon, P.J., Schreck, R., Henkel, T., Chen, C.-H., Maher, M., Baeuerle, P.A. and Rosen C. (1991). Isolation of a rel- related human cDNA that potentially encodes the 65-kD subunit of NF-κB Science 251: 1490-1493
Patents:
Method for identifying substances directed against myocardial cell hypertrophy
PCT/WO 02/097128A2 published 05.12. 2002
Inventors: T. Henkel, V. Rönicke, B. Navé
Applicant: MediGene AG
Herz- und Skelettmuskelspezifische Nukleinsäure, ihre Herstellung und Verwendung.
German Patent issued 15.6. 2000
Inventors: T. Henkel, M. Hofmann & H. Domdey
Applicant: MediGene AG
Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces
PCT/EP97/02840 filed 30.05 1997
Inventors: B. Steipe, H. Bruhn, M. Funk, T. Henkel
Applicant: MediGene AG
Epstein-Barr virus transcription factor binding assay
US Patent 5,679,525 issued 21.10. 1997
Inventors: T. Henkel & M. G. Peterson
Applicant: Tularik Inc.
Process for inhibiting the transcription of genes
US Patent 6,090,542 issued 18.7. 2000
Inventors: T. Henkel & P.A. Bäuerle
Applicant: Boehringer Ingelheim International GmbH et al.
Josef Rüschoff
Chief Medical Officer & Co-Founder
Read More
Prof. Josef Rüschoff
Chief Medical Officer
Co-Founder
Dr. Rüschoff’s experience and passion for clinical pathology guarantees that Targos biomarker research & development leads to innovation in clinical diagnostic routine. As a cornerstone of Targos outstanding pathology quality, he has led the Targos efforts in supporting the approval of breakthrough diagnostic tests such as for Her2 or PD-L1.
Reinhard Büttner
Chief Scientific Officer & Co-Founder
Read More
Prof. Dr. med. R. Büttner
Chief Scientific Officer
Co-Foundert
Dr. Büttner’s simultaneous experience as Director of Pathology, University Cologne enables him to inspire Targos in its pursuit of cutting-edge technology for molecular pathology in clinical research & development.
Professor Reinhard Büttner has successfully implemented NGS technology into health care diagnostic routine for lung cancer.
Gudrun Bänfer
Head of Advance - Training & Consulting
Read More
Dr. Gudrun Bänfer
Head Targos Advance
Training & Consulting
With a background in science and project management Dr. Bänfer shaped the Targos Advance Training Program since 2010 to today’s reputation. Working closely with trainers from the Targos international pathology network, the program has global presence and 3.500 pathologists were trained in the use of biomarker assays in oncology such as Her2, PD-L1 or NGS. The Targos Advance Program fulfills the mission to bring highly standardized biomarkers to clinical routine.
Petra Heinmöller
Director of Quality Management
Read More
Dr. Petra Heinmöller
Director Quality Management
The team led by Dr. Heinmöller supervises the compliance of all Targos processes in accordance with Good Clinical Practice and US-CAP and CLIA requirements. Data generated by Targos for Drug & Companion Diagnostic approvals have been successfully submitted to the FDA and EMA. PH has structured QM at Targos to comply with many dozens of inspections and audits.
Bharat Jasani
Director of Pathology
Read More
Prof. Dr. Bharat Jasani
Director Pathology
Dr. Jasanis forty years of rich experience in academic pathology and biomarker research in Cardiff, UK, helped Targos to significantly enhance its internal pathology department, which he leads since 2015. Recently he is driving vigorously digital pathology development for multiplex IHC and Immunofluoresence applications at Targos.
George L. Kumar
Vice President of Marketing and Scientific Affairs.
Read More
Dr. George Kumar
Vice President, Targos Inc, USA
Scientific Affairs & Marketing
Dr. Kumar has added his vast experience in developing scientific key opinion leader networks globally.
The high reputation of the Targos network of outstanding pathologists is channeled into an endless reservoir of expertise for clinical biomarker research, the Targos Advance expert training courses or joint publications.
Oliver Stoss
Director of Service Operations, President Targos Inc.
Read More
Dr. Oliver Stoss
Director Service Operations
As a skilled scientist and informatician Dr. Stoss has structured and managed Targos processes since 2005 up to today’s level of quality and flexibility. Dr. Stoss is a seasoned leader and intelligently has developed the Targos service portfolio to the current breadth and depth.
